Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8

Leukemia. 2002 Jul;16(7):1390-3. doi: 10.1038/sj.leu.2402634.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Chromosomes, Human, Pair 8*
  • Hematopoiesis* / genetics
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / physiopathology
  • Middle Aged
  • Philadelphia Chromosome
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Trisomy*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate